Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Diamond

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Haematologica|October 15, 2020
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)Francesco Maura, Anna Dodero, Cristiana Carniti, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Nature Communications|September 2, 2023
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myelomaDavid G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Haematologica|October 15, 2020
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)Francesco Maura, Anna Dodero, Cristiana Carniti, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Hemasphere|April 20, 2026
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myelomaChrissy Baker, Elizabeth Hill, Dickran Kazandjian, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Nature Communications|September 2, 2023
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myelomaDavid G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Pageof 5